Cantor Fitzgerald Forecasts Cabaletta Bio FY2025 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Cabaletta Bio in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($2.19) per share for the year. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share.

CABA has been the subject of several other research reports. TD Cowen upgraded Cabaletta Bio to a “strong-buy” rating in a report on Friday, November 29th. Evercore ISI lowered shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and dropped their price target for the company from $15.00 to $6.00 in a research report on Friday, December 20th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Cabaletta Bio in a report on Friday, January 17th. William Blair reiterated an “outperform” rating on shares of Cabaletta Bio in a research note on Monday, November 18th. Finally, UBS Group began coverage on Cabaletta Bio in a research note on Thursday, October 10th. They issued a “buy” rating and a $10.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $24.38.

Cabaletta Bio Stock Performance

CABA stock opened at $2.54 on Thursday. The business has a 50-day simple moving average of $2.65 and a two-hundred day simple moving average of $4.30. The company has a market capitalization of $124.16 million, a P/E ratio of -1.18 and a beta of 2.46. Cabaletta Bio has a 52-week low of $1.76 and a 52-week high of $26.35.

Institutional Investors Weigh In On Cabaletta Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Cabaletta Bio during the third quarter valued at about $32,000. Point72 DIFC Ltd bought a new position in Cabaletta Bio during the 3rd quarter valued at approximately $33,000. Avanza Fonder AB purchased a new stake in Cabaletta Bio in the fourth quarter worth $40,000. China Universal Asset Management Co. Ltd. boosted its holdings in Cabaletta Bio by 65.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company’s stock valued at $44,000 after acquiring an additional 3,724 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in Cabaletta Bio during the 3rd quarter valued at $67,000.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.